MORRIS PLAINS, N.J.
Immunomedics said Thursday federal health regulators have halted a study of the company's experimental pancreatic cancer drug after one patient received an incorrect dose of the medication.
The company said the Food and Drug Administration placed a clinical hold on the study after investigators discovered the patient received a higher-than-prescribed dose. The patient "remains on study with no critical toxicity," the company said in a statement.
The company is working with the FDA to file the necessary paperwork to resume the trial.
Company shares fell 25 cents, or 6.7 percent, to close at $3.50.